Loading clinical trials...
Loading clinical trials...
A Phase 1 Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients With Neovascular AMD
Conditions
Interventions
JSM6427
Locations
9
United States
Retina Vitreous Associates Medical Group
Beverly Hills, California, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
William Beaumont Research Institute
Royal Oak, Michigan, United States
Dean McGee Eye Institute
Oklahoma City, Oklahoma, United States
Palmetto Retina Center
West Columbia, South Carolina, United States
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States
Start Date
September 1, 2007
Primary Completion Date
December 1, 2008
Completion Date
December 1, 2009
Last Updated
September 21, 2010
NCT05913063
NCT07446582
NCT06779773
NCT06990269
NCT06970665
NCT07160179
Lead Sponsor
Jerini Ophthalmic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions